Beta Drugs Ltd

Beta Drugs Ltd Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Beta Drugs Ltd

₹ 1,380 1.85%
18 Apr 3:56 p.m.
Company website NSE - SM : BETA
About

Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.[1]

Key Points

Product Portfolio
The company's product portfolio includes 63 molecules and ~110 SKUs primarily in the oncology segment in the areas of solid tumor, Hematology, and Supportive care. [1]

Website NSE - SM
  • Market Cap ₹ 1,327 Cr.
  • Current Price ₹ 1,380
  • High / Low ₹ 1,595 / 660
  • Stock P/E 62.5
  • Book Value ₹ 112
  • Dividend Yield 0.00 %
  • ROCE 27.9 %
  • ROE 21.7 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 22.7% CAGR over last 5 years
  • Company's median sales growth is 21.4% of last 10 years

Cons

  • Stock is trading at 12.3 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Edit Columns
Loading peers table ...

Half Yearly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2019 Mar 2020 Sep 2020 Mar 2021 Sep 2021 Mar 2022 Sep 2022 Mar 2023 Sep 2023
34 31 35 45 60 65 78 80 92
28 26 28 36 47 53 62 64 73
Operating Profit 7 5 7 9 13 13 16 15 19
OPM % 19% 16% 19% 19% 21% 19% 20% 19% 21%
0 0 0 0 1 0 0 1 1
Interest 0 0 0 0 0 0 0 1 1
Depreciation 1 2 2 3 2 3 3 3 3
Profit before tax 6 3 4 6 10 10 13 12 16
Tax % 27% 10% 24% 33% 29% 30% 25% 26% 25%
4 3 3 4 7 7 10 9 12
EPS in Rs 4.17 3.21 3.18 4.08 7.63 7.19 10.09 9.48 12.60
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
3 3 1 0 26 42 51 58 65 79 125 158 172
3 3 1 0 23 34 41 48 54 64 99 126 138
Operating Profit 0 0 0 -0 3 7 9 10 12 15 25 31 35
OPM % 5% 8% 14% -0% 11% 17% 19% 18% 18% 19% 20% 20% 20%
-0 -0 -0 -0 0 0 0 0 0 1 1 1 1
Interest -0 0 0 0 1 1 1 1 1 1 0 1 1
Depreciation 0 0 0 0 1 1 2 2 3 5 5 6 6
Profit before tax 0 0 0 -0 1 5 7 7 9 10 20 25 28
Tax % -0% -0% -0% -0% -0% 19% 1% -3% 21% 29% 29% 25%
0 0 0 -0 1 4 7 8 7 7 14 19 21
EPS in Rs 40.00 40.00 20.00 -1.09 11.19 42.28 7.82 8.91 7.39 7.26 14.82 19.58 22.08
Dividend Payout % -0% -0% -0% -0% -0% -0% -0% -0% -0% -0% -0% -0%
Compounded Sales Growth
10 Years: 48%
5 Years: 26%
3 Years: 34%
TTM: 20%
Compounded Profit Growth
10 Years: 85%
5 Years: 23%
3 Years: 38%
TTM: 28%
Stock Price CAGR
10 Years: %
5 Years: 69%
3 Years: 112%
1 Year: 75%
Return on Equity
10 Years: 20%
5 Years: 18%
3 Years: 18%
Last Year: 22%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 0 0 0 1 1 1 9 9 10 10 10 10 10
Reserves 0 0 0 0 1 5 24 32 47 54 68 87 98
1 1 1 5 8 8 8 8 9 5 7 6 3
1 0 0 2 5 9 9 16 17 18 27 32 45
Total Liabilities 2 2 1 8 15 23 50 65 82 86 111 134 155
1 1 1 1 7 8 13 12 32 28 34 35 36
CWIP -0 -0 -0 6 -0 -0 1 15 0 2 -0 -0 -0
Investments -0 -0 -0 -0 -0 -0 -0 2 6 7 7 7 6
1 1 1 2 8 15 35 36 44 50 70 93 114
Total Assets 2 2 1 8 15 23 50 65 82 86 111 134 155

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
-0 -0 0 1 -0 5 17 8 6 12 19 10
-0 -0 -0 -6 -2 -2 -11 -16 -14 -3 -13 -6
-0 0 -0 4 3 -3 5 -1 9 -4 1 -2
Net Cash Flow -0 -0 -0 0 0 0 12 -9 1 4 7 2

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 88 47 77 112 61 92 104 109 117 96 92 101
Inventory Days 69 123 3,115 69 37 38 76 64 65 44 60
Days Payable 58 34 5,256 97 108 82 121 97 111 101 102
Cash Conversion Cycle 88 58 166 -2,029 33 21 60 64 84 49 34 59
Working Capital Days 36 66 130 -758 34 50 75 70 87 83 63 83
ROCE % 3% 12% 10% -3% 22% 49% 29% 18% 17% 16% 27% 28%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
66.68% 66.68% 66.71% 66.71% 66.71% 66.71% 66.71% 66.73% 66.73% 66.73% 66.73% 66.73%
0.00% 0.00% 0.00% 0.00% 0.00% 0.29% 0.29% 0.29% 0.29% 0.32% 0.32% 0.32%
0.27% 0.28% 0.29% 0.29% 0.29% 0.04% 0.04% 0.04% 0.04% 0.02% 0.02% 0.06%
33.06% 33.03% 33.01% 33.00% 33.00% 32.96% 32.96% 32.94% 32.93% 32.93% 32.92% 32.87%
No. of Shareholders 5075426757621,2961,4071,4441,4241,4511,7221,9282,116

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings